Chemed (NYSE:CHE) reported quarterly earnings of $4.74 per share which beat the analyst consensus estimate of $4.65 by 1.94 percent. This is a 6.32 percent decrease over earnings of $5.06 per share from the same period last year.
Inhibikase Therapeutics Announces Dosing Of First Patient In Its Phase 2a ‘201’ Clinical Trial Of IkT-148009 To Treat Parkinson’s Disease
nhibikase Therapeutics, Inc. (NASDAQ:IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced dosing of the
